Planet Labs (PL) Is Up 42.8% After Strong FY26 Guidance and AI Pelican Milestone - Has The Bull Case Changed?

• Planet Labs PBC recently reported past third-quarter 2025 results, with revenue rising to US$81.25 million from US$61.27 million a year earlier, but net loss widening to US$59.19 million and basic loss per share increasing to US$0.19.
• Alongside releasing first-light images from its new AI-enabled Pelican satellites, the company issued fourth-quarter and fiscal 2026 revenue guidance ahead of analyst expectations, underscoring how its newer high-resolution, AI-ready constellation is beginning to feed into a larger, more solution-focused business model.
• Now we’ll explore how this stronger-than-expected guidance, underpinned by AI- and defense-driven demand, reshapes Planet Labs’ existing investment narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Planet Labs PBC Investment Narrative Recap

To own Planet Labs, you need to believe that its Earth imaging data can scale into a durable, software-like, AI-enabled platform, even while the company is still loss-making. The latest quarter reinforced that story by pairing strong revenue growth and raised guidance with wider net losses, making the near term catalyst the pace of AI and defense contract wins, while the biggest risk remains the cash and earnings pressure from funding its new satellite fleets.

Among recent updates, the launch of the AI-enabled Pelican-5 and Pelican-6 satellites is especially relevant, because it connects directly to Planet’s guidance commentary about AI- and defense-driven demand. These higher resolution, edge-compute capable satellites are central to turning raw imagery into higher value intelligence products, which is where much of the optimism around future revenue growth and contract momentum is currently anchored.

Yet, despite the excitement, investors should be aware that heavy satellite and AI investment could still...

Read the full narrative on Planet Labs PBC (it's free!)

Planet Labs PBC's narrative projects $409.3 million revenue and $29.2 million earnings by 2028. This requires 17.8% yearly revenue growth and a $135.7 million earnings increase from -$106.5 million today.

Uncover how Planet Labs PBC's forecasts yield a $14.55 fair value, a 20% downside to its current price.

Exploring Other Perspectives

Eight members of the Simply Wall St Community currently see fair value for Planet Labs anywhere between about US$2.08 and US$14.55 per share. With that spread of views, it is worth weighing how much confidence you place in AI and defense demand offsetting ongoing losses and capital intensity before deciding where you stand.

Explore 8 other fair value estimates on Planet Labs PBC - why the stock might be worth as much as $14.55!

Build Your Own Planet Labs PBC Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Planet Labs PBC research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Planet Labs PBC research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Planet Labs PBC's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com